As the Alzheimer’s disease research community has transitioned towards a biological definition of the disease,7 the emergence of anti-Aβ therapies approved by the Food and Drug Administration (FDA) and upcoming clinical trials emphasize the importance of validated blood biomarkers for detecting abnormal Aβ and tau pathology. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.